Short Interest in Hims & Hers Health, Inc. (NYSE:HIMS) Grows By 6.2%

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 33,840,000 shares, an increase of 6.2% from the October 15th total of 31,870,000 shares. Based on an average daily trading volume, of 10,980,000 shares, the short-interest ratio is currently 3.1 days. Approximately 19.1% of the company’s shares are sold short.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the sale, the insider now owns 159,796 shares of the company’s stock, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now directly owns 23,917 shares of the company’s stock, valued at approximately $362,342.55. This trade represents a 22.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 996,961 shares of company stock worth $20,256,416. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC increased its position in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new stake in Hims & Hers Health in the 2nd quarter worth approximately $111,000. CWM LLC grew its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the period. Finally, Quarry LP lifted its stake in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after buying an additional 2,913 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research analyst reports. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, TD Cowen raised their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.71.

Hims & Hers Health Trading Up 7.4 %

NYSE:HIMS traded up $1.56 on Tuesday, hitting $22.55. The company’s stock had a trading volume of 14,267,494 shares, compared to its average volume of 9,344,310. The firm has a market capitalization of $4.93 billion, a P/E ratio of 50.46 and a beta of 1.06. Hims & Hers Health has a one year low of $7.50 and a one year high of $30.44. The stock has a fifty day moving average of $19.90 and a two-hundred day moving average of $18.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) EPS. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.